Previous Article | Next Article 
Journal of Clinical Microbiology, September 1998, p. 2419-2422, Vol. 36, No. 9
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Prevalence of and Factors Associated with Visceral
Leishmaniasis in Human Immunodeficiency Virus Type 1-Infected
Patients in Southern Spain
Juan A.
Pineda,1,*
José A.
Gallardo,1
Juan
Macías,1
Juan
Delgado,1
Carmen
Regordán,2
Francisco
Morillas,3
Federico
Relimpio,1
Joaquina
Martín-Sánchez,3
Armando
Sánchez-Quijano,1
Manuel
Leal,1 and
Eduardo
Lissen1
Viral Hepatitis and AIDS Study
Group1 and
Department of
Microbiology,2 Hospital Universitario Virgen
del Rocío, 41013-Seville, and
Department of
Parasitology, Facultad de Farmacia, Universidad de Granada,
18071-Granada,3 Spain
Received 3 March 1998/Returned for modification 20 April
1998/Accepted 8 June 1998
 |
ABSTRACT |
The actual prevalence of visceral leishmaniasis among human
immunodeficiency type 1 (HIV-1)-infected patients in the Mediterranean basin remains unknown. There is also controversy about the risk factors
for Leishmania infantum and HIV-1 coinfection. To appraise the prevalence of visceral leishmaniasis in patients infected with
HIV-1 in southern Spain and to identify factors associated with this
disease, 291 HIV-1 carriers underwent a bone marrow aspiration,
regardless of their symptoms. Giemsa-stained samples were searched for
Leishmania amastigotes. Thirty-two (11%) patients showed
visceral leishmaniasis. Thirteen (41%) patients had subclinical cases
of infection. Centers for Disease Control and Prevention (CDC) clinical
category C was the factor most strongly associated with this disease
(adjusted odds ratio [OR], 1.88 [95% confidence interval, 1.22 to
2.88]), but patients with subclinical cases of infection were found in
all CDC categories. Female sex was negatively associated with visceral
leishmaniasis (adjusted OR, 0.42 [95% confidence interval, 0.18 to
0.97]). Intravenous drug users showed a higher prevalence than the
remaining patients (13.3 versus 4.9%; P = 0.04), but
such an association was not independent. These results show that
visceral leishmaniasis is a very prevalent disease among HIV-1-infected
patients in southern Spain, with a high proportion of cases being
subclinical. Like other opportunistic infections, subclinical visceral
leishmaniasis can be found at any stage of HIV-1 infection, but
symptomatic cases of infection appear mainly when a deep
immunosuppression is present. There is also an association of this
disease with male sex and intravenous drug use.
 |
INTRODUCTION |
Visceral leishmaniasis is a frequent
disease among human immunodeficiency virus type 1 (HIV-1)-infected
patients in countries of the Mediterranean basin (15, 19).
It also seems to be an emerging problem among this population in
certain areas where leishmaniasis is not endemic (2, 20).
Leishmania amastigotes have been found in 17% of
HIV-1-seropositive individuals in Spain who showed at least a symptom
or laboratory data suggesting that they had leishmaniasis
(3). The reported visceral leishmaniasis incidence in AIDS
patients in Sicily was 4.9% during the period from 1985 to 1994 (15). However, these rates have been obtained from studies
carried out with symptomatic patients. Because subclinical cases of
this disease are frequent in HIV-1-seropositive individuals (22), the data presented above could underestimate the true extent of Leishmania infantum and HIV-1 coinfection in our
area. On the other hand, preliminary data suggest that visceral
leishmaniasis could be a cofactor in HIV-1 disease progression
(8). For these reasons, surveys that assess the actual
prevalence of visceral leishmaniasis in this population are necessary.
In most case series visceral leishmaniasis was associated with advanced
HIV-1 disease (15, 19, 23). This parasitic disease was also
more frequent in intravenous drug users in some studies (6,
15) but not in others (19, 23). Nevertheless, these observations have also been reported in retrospective surveys dealing
with symptomatic patients. Analyses of risk factors in unselected
HIV-1-infected populations are needed. These studies have not been
performed to date, probably due to methodological problems. In fact,
the tools commonly used for the diagnosis of leishmaniasis in
large-scale epidemiological surveys, such as serology or the leishmanin
skin test, have low sensitivities when they are used to test
HIV-1-infected patients (14, 15, 19). Consequently, invasive
methods such as parasite detection in tissue samples, must be used.
We report herein the prevalence of visceral leishmaniasis in a group of
HIV-1 infected patients with a wide spectrum of clinical conditions
determined by searching for amastigotes in bone marrow aspirates. We
also analyzed the association of this disease with potential risk
factors in this population.
 |
MATERIALS AND METHODS |
Patients.
All 335 HIV-1-infected patients without severe
clotting disorders who attended the Viral Hepatitis and AIDS Study
Group's unit between January 1993 and February 1997 were invited to
participate in this cross-sectional study. Nine further
HIV-seropositive individuals with a serious clotting disorder were seen
at our unit during this period. This unit provides care to both
inpatients and outpatients coming from Andalusia (southern Spain). In
this area all HIV-1-infected individuals who seek medical care are seen
in tertiary-care units like this one. Patients were invited to
participate in the study regardless of their symptoms, and 291 (87%)
agreed to participate. All of them answered an epidemiological
questionnaire, had clinical and immunological evaluations, and
underwent a sternal bone marrow aspiration.
The study was designed and performed according to the Helsinki
Declaration and was approved by the Ethics Committee of the Hospital
Universitario Virgendel Rocío; all patients gave their written
informed consent to participate.
Laboratory methods.
Bone marrow aspirate samples were
partially smeared on slides and were stained with Giemsa stain. Both
thin and thick films were made. Examinations of the smears were carried
out by an expert parasitologist at ×1,000 magnification for at least
20 min. Mononuclear cells from a part of the bone marrow aspirate taken
from the last 166 patients included in the study were isolated by
density gradient centrifugation on Ficoll and were cryopreserved in
liquid nitrogen. Due to limitations in laboratory facilities,
Leishmania cultures could be done only for a restricted
number of patients; thus, cultures were performed retrospectively for
the first eight individuals with a positive Giemsa staining result and
for whom a cryopreserved sample was available. Myelocultures were also
done with fresh bone marrow aspirate taken from 32 patients
consecutively included in the study between February 1996 and April
1996. Samples were seeded into Evans modified Tobie's medium
supplemented with RPMI, and the cultures were followed for at least 1 month. The parasites cultured were characterized by
electrophoretic analysis on starch gels of 15 enzymatic loci by using
the techniques and nomenclature of the World Health Organization
Collaborating Centre in Montpellier, France (24). The full
enzyme names, codes, and reference strains that were used were reported
by Gramiccia et al. (16). Smear examinations and cultures
were performed in two independent laboratories. The parasitologists who
carried out microbiological studies were blinded to the clinical
condition of the patients.
CD4+ cell counts were determined by standard flow
cytometry.
Diagnostic criteria.
Visceral leishmaniasis was diagnosed
when Leishmania amastigotes were seen by direct
visualization. Subclinical visceral leishmaniasis was defined as
described elsewhere (22); a case was considered subclinical
if the following criteria were met: the patient had no fever, no
splenomegaly, or a hemoglobin level of <9 g/dl. If these symptoms were
present, they had to be attributable to another concomitant disease and
to disappear after specific treatment for that disease, without
antileishmanial therapy. All cases that did not fulfill these criteria
were considered symptomatic visceral leishmaniasis. HIV-1 infection was
categorized according to the 1993 classification of the Centers for
Disease Control and Prevention (CDC) (9).
Statistical analysis.
The continuous variables are expressed
as median (range), and the prevalence rates are expressed as a
percentage. The associations between visceral leishmaniasis and the
following parameters were assessed: age, sex, living area (urban,
suburban, or rural), risk factors for HIV-1 infection, CDC clinical
category, previous leishmaniasis diagnosis, and CD4+ cell
count. Both univariate and multivariate analyses were performed. In the
univariate analysis, continuous variables were compared by the
Mann-Whitney U test. Frequencies were compared by the
2
test or the Fisher test. All variables having a univariate association with visceral leishmaniasis with a significance level of <0.1 were
entered into a stepwise logistic regression model. Since cultures were
not done for the entire population, all the prevalence rates and
statistical analyses are based on the results of direct visualization
of the bone marrow aspirate smears. Statistical analyses were performed
by using the software package SPSS.
 |
RESULTS |
Characteristics of the population studied.
All patients were
white. The median age of the group was 32 years (range, 17 to 75 years). The median CD4+ cell count was 172 × 106 cells/liter (range, 1 × 106 to
1,520 × 106 cells per liter). Two hundred ten
individuals were intravenous drug users, 38 were homosexual men,
36 were heterosexuals, and 7 reported no risk factors for HIV
infection. Other data for the population are summarized in Table
1.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Frequency of visceral leishmaniasis in relation to sex,
living area, risk factors for HIV-1 infection, CDC clinical
category, and history of previous leishmaniasis
|
|
Visceral leishmaniasis prevalence.
Leishmania
amastigotes were found in the bone marrow aspirates of 32 (11%)
patients. Leishmania promastigotes were isolated from five
of the eight cryopreserved, Giemsa stain-positive samples analyzed. On
the other hand, 1 of 32 fresh aspirates which were cultured showed
amastigotes by Giemsa staining; only from this fresh sample were
promastigotes isolated. All isolates obtained by culture were
identified as L. infantum MON-1.
Thirteen (4.5%) patients met the criteria for subclinical visceral
leishmaniasis; this represents 41% of the total visceral leishmaniasis
patients. On the other hand, 179 patients did not have fever when they
were included in the study; remarkably, 11 (6.1%) of them were found
to have amastigotes in their bone marrow aspirates.
Associations between visceral leishmaniasis and other
parameters.
The ages were similar among patients with and without
visceral leishmaniasis (32 years [range, 24 to 50 years] versus 32 years [range, 17 to 75 years]; P = 0.78).
CD4+ cell counts were lower in individuals with this
disease (55 × 106 cells/liter [range, 1 × 106 to 1,358 × 106 cells/liter] versus
200 × 106 cells/liter [range, 1 × 106 to 1,520 × 106 cells/liter];
P = 0.005). On univariate analysis, male sex, injection drug use, and CDC clinical category C were also associated with visceral leishmaniasis (Table 1). The stepwise logistic
regression procedure sequentially selected CDC clinical category C
(odds ratio [OR], 1.88 [95% confidence interval {CI}, 1.22 to
2.88]; P = 0.002] and female sex (OR, 0.42 [95% CI, 0.18 to 0.97]; P = 0.03) as the
variables independently associated with this parasitic disease. The
association between intravenous drug use and visceral leishmaniasis was
close to statistical significance level (OR, 1.56 [95% CI, 0.90 to
2.66]; P = 0.08).
The proportions of males (75%), intravenous drug users (70%), and
patients in CDC clinical category C (39%) among patients who did not
agree to be included in the study were not statistically different from
those found among individuals who participated in the study
(P = 0.35, P = 0.95, and
P = 0.17, respectively).
There was no association between subclinical visceral leishmaniasis and
the CDC clinical category. In fact, the frequency of subclinical cases
among patients included in category C was 4.7%, whereas it was 4.2%
among those included in category A or B (P = 0.82)
(Fig. 1). In the same way, after
categorizing CD4+ cell counts, the frequency of subclinical
visceral leishmaniasis was similar in patients with CD4+
cell counts of
200 × 106 cells/liter and those with
more than 200 × 106 CD4+ cells/liter.
Thus, 8 of 155 (5.2%) patients in the first subgroup and 5 of 136 (3.7%) patients in the second subgroup had subclinical disease
(P = 0.54). In contrast, symptomatic cases were more
frequent among patients in CDC clinical category C (P = 0.0008) and in those with CD4+ cell counts of
200 × 106/liter (P = 0.001) (Fig. 1).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
Frequency of subclinical and symptomatic visceral
leishmaniasis in relation to CDC clinical category (A) and
CD4+ cell counts (cells per microliter) (B). The numbers
inside the bars indicate the number of patients in each subgroup. VL,
visceral leishmaniasis.
|
|
 |
DISCUSSION |
Our results indicate that visceral leishmaniasis is highly
prevalent among HIV-1-infected patients in southern Spain. In fact, roughly 1/10 of this population had this disease, with nearly half of
the patients having subclinical infection; even as many as 6% of
afebrile individuals harbored L. infantum amastigotes in
their bone marrow. The disease in most asymptomatic patients probably
would have gone undetected in a retrospective case series. This fact
explains why fever was present in 87 to 95% of the patients in a large
case series (11, 19, 25) of visceral leishmaniasis in
patients with HIV-1 infection and also why subclinical infections were
described as exceptional in the first studies dealing with this issue
(10, 11, 23). Therefore, these findings prove that the
frequencies of L. infantum and HIV-1 coinfection based on
studies performed with symptomatic patients were inaccurate.
This study could be biased because patients with severe
immunodeficiency probably seek medical care more frequently than those with less advanced disease. This would lead to a higher proportion of
strongly immunosuppressed individuals in the group analyzed here than
in the whole HIV-1-infected population. In such a case, the prevalence
of visceral leishmaniasis that we obtained would be an overestimation.
However, this inherent bias should not be relevant, since patients with
a wide spectrum of immune system impairments were included in this
study. Anyway, our population represents the cluster of
HIV-1-seropositive patients who attend hospitals in our area. Another
limitation of this study may be that the diagnosis of leishmaniasis was
based on direct visualization of amastigotes. Theoretically, this
method can yield false-negative results if parasites are scanty or if
the examiner is unskilled. Indeed, L. infantum has been
detected by myeloculture (7, 13) or PCR (21) in
individuals for whom direct examination of bone marrow aspirates was
negative. However, culture is time-consuming and is therefore difficult
to use in large-scale epidemiological surveys like the one described
here. We performed cultures with fresh samples from 32 consecutive
patients, and no further visceral leishmaniasis cases were detected.
This suggests that the frequencies obtained in this study would have
been very similar if myelocultures had been carried out for all
patients. On the contrary, the culture of cryopreserved samples turned
out to be negative for some patients for whom amastigotes were observed
by direct examination. This fact has also been reported in other
studies (21, 23) and could be at least in part a consequence
of having used Ficoll-purified material. Despite the diversity of
zymodemes isolated from HIV-Leishmania-coinfected patients
(4, 5) and from sandflies (17) in our area, we found only L. infantum MON-1. The low number of cultures
that we performed probably accounts for this fact.
We have found visceral leishmaniasis to be independently associated
with the CDC clinical category. This finding confirms the relationship
observed in most retrospective case series between this parasitic
disease and advanced stages of HIV-1 infection (11, 15, 19, 23,
25). However, the frequency of subclinical cases was similar
among patients with severe immunodeficiency and those with less
advanced HIV-1 disease. These data indicate that visceral leishmaniasis
may take place at any stage of HIV-1 infection, but it essentially
becomes symptomatic in patients who are highly immunosuppressed. In
this sense visceral leishmaniasis is similar to other AIDS-related
opportunistic illnesses, such as tuberculosis, cytomegalovirus disease,
or cryptococosis, in which silent infection may be present in any
HIV-1-seropositive patient, whereas overt disease appears only in
highly immunosuppressed patients.
The relationship between L. infantum and HIV-1 coinfection
and injection drug use is a matter of controversy. Declared cases of
visceral leishmaniasis are more frequent among AIDS patients who are or
were intravenous drug addicts than among those who acquired HIV-1
infection in other ways (6). Also, L. infantum zymodemes from coinfected intravenous drug users show a higher variability than zymodemes from HIV-1-seronegative patients or dogs
(4, 5, 16, 17). On the basis of these findings, some
researchers have hypothesized that this parasite could be transmitted
through the sharing of needles (4). However, the heterogeneity of zymodemes isolated from sandflies in our area is also
high (17), so insect vector transmission cannot be
completely ruled out. Moreover, no direct evidence of the spread of
L. infantum through the sharing of needles has yet been
obtained. In this study visceral leishmaniasis was more frequent in
intravenous drug users, but such an association was not independent of
clinical category and sex on multivariate analysis, although
statistical significance was almost reached. Consequently, no definite
conclusions on that subject can be drawn from this study, but in our
opinion, transmission through the sharing of needles is very probable. The fact that L. infantum can be found in peripheral blood
smears from some asymptomatic HIV-1-infected patients (12)
supports this hypothesis.
Visceral leishmaniasis was independently associated with male sex.
Other epidemiological studies performed in Mediterranean countries have
found leishmaniasis to occur more frequently in men (15,
18), but other surveys failed to confirm such a difference (1). This finding is intriguing, and a satisfactory
explanation is not easy to give. It could simply be a reflection of
what happens in the south of Europe, where most drug addicts are males.
Anyhow, the association of this parasitic disease with sex and drug
abuse in people coinfected with HIV and L. infantum will
require further attention.
The proportions of Leishmania-infected patients in the
present study living in rural, suburban, and urban areas were similar. In other studies urban foci of L. infantum and HIV-1
coinfection have also been detected, such as in Campania, Italy
(15). These findings suggest that modes of transmission
other than phlebotomine bites may be involved in the spread of L. infantum among HIV-1-infected patients. Sharing of needles among
intravenous drug users again comes to mind as a possible explanation.
 |
ACKNOWLEDGMENTS |
We are grateful to technicians Mercedes Olivera and Antonio
Gayoso, to nurses Jose M. García, Manuela Mora, María
L. Amo, Concepción Martínez, Concepción Almoguera,
Maite Nuño, Rosario Martínez, Jacinto Flores,
María O. Román, and Manuel J. García, and to the
patients, without whose collaboration this study could not have been
accomplished.
This study was partly supported by grants from the Plan Andaluz de
Investigación (group code 3105) and the Servicio Andaluz de Salud
(expediente 276/97).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Viral Hepatitis
and AIDS Study Group, Hospital Universitario Virgen del Rocío,
Avenida Manuel Siurot s/n, 41013-Sevilla, Spain. Phone: 34-5-4248154. Fax: 34-5-4248249. E-mail: vergara{at}cica.es.
 |
REFERENCES |
| 1.
|
Acedo Sánchez, C.,
J. Martín Sánchez,
I. D. Vélez Bernal,
M. C. Sanchís Marín,
M. Louassini,
J. A. Maldonado, and F. Morillas Márquez.
1996.
Leishmaniasis eco-epidemiology in the Alpujarra region (Granada province, southern Spain).
Int. J. Parasitol.
25:303-310.
|
| 2.
|
Albrecht, H.,
I. Sobottka,
C. Emminger,
H. Jablonowski,
G. Just,
A. Stoehr,
T. Kubin,
B. Salzberger,
T. Lutz, and J. van Lunzen.
1996.
Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani.
Arch. Pathol. Lab. Med.
120:189-198[Medline].
|
| 3.
|
Alvar, J.,
B. Gutiérrez-Solar,
R. Molina,
R. López-Vélez,
A. García-Camacho,
P. Martínez,
F. Laguna,
E. Cercenado, and A. Galmes.
1992.
Prevalence of Leishmania infection among AIDS patients.
Lancet
339:1427[Medline].
|
| 4.
|
Alvar, J.,
B. Gutiérrez-Solar,
I. Pachón,
E. Calbacho,
M. Ramírez,
R. Vallés,
J. L. Guillén,
C. Cañavete, and C. Amela.
1996.
AIDS and Leishmania infantum. New approaches for a new epidemiological problem.
Clin. Dermatol.
14:541-546[Medline].
|
| 5.
|
Alvar, J., and M. Jiménez.
1994.
Could infected drug users be potential Leishmania infantum reservoirs?
AIDS
8:6.
|
| 6.
|
Amela, C.,
D. López-Gay,
J. C. Alberdi, and J. Castilla.
1996.
Injecting drug use as risk factor for visceral leishmaniasis in AIDS patients.
Eur. J. Epidemiol.
12:91-92[Medline].
|
| 7.
|
Berenguer, J.,
S. Moreno,
E. Cercenado,
J. C. L. Bernaldo de Quirós,
A. García de la Fuente, and E. Bouza.
1989.
Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV).
Ann. Intern. Med.
111:129-132.
|
| 8.
|
Cacopardo, B.,
L. Nigro,
W. Preiser,
A. Fama,
M. I. Satariano,
J. Braner,
B. M. Celesia,
B. Weber,
R. Russo, and H. W. Doerr.
1996.
Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania coinfected patients despite treatment.
Trans. R. Soc. Trop. Med. Hyg.
90:434-435[Medline].
|
| 9.
|
Centers for Disease Control.
1992.
1993 revised classification system for HIV and expanded surveillance case definition for AIDS among adolescents and adults.
Morbid. Mortal. Weekly Rep.
41:1-19.
|
| 10.
|
Condom, M. A.,
B. Clotet,
G. Sirera,
F. Milla, and M. Foz.
1989.
Asymptomatic leishmaniasis in the acquired immunodeficiency syndrome.
Ann. Intern. Med.
111:767-768.
|
| 11.
|
Dedet, J. P.,
M. Lambert, and F. Pratlong.
1995.
Leishmanioses et infection par le virus de l'inmunodeficiency humaine.
Presse Med.
24:1036-1040.
|
| 12.
|
Delgado, J.,
J. A. Pineda,
J. Macías,
C. Regordán,
J. A. Gallardo,
M. Leal,
A. Sánchez-Quijano, and E. Lissen.
1998.
Low sensitivity of peripheral blood smear for the diagnosis of subclinical visceral leishmaniasis in HIV-1 infected patients.
J. Clin. Microbiol.
36:315-316[Abstract/Free Full Text].
|
| 13.
|
Dereure, J.,
J. Reynes,
F. Pratlong,
I. Lamaury,
J. A. Rioux,
F. Janbon, and J. P. Dedet.
1995.
Visceral leishmaniasis in HIV-1 infected patients in the south of France.
Bull. W. H. O.
73:245-246[Medline].
|
| 14.
|
Gallardo, J. A.,
J. A. Pineda,
J. Macías,
R. Torronteras, and E. Lissen.
1996.
Specificity of a commercial indirect immunofluorescence technique in the diagnosis of visceral leishmaniasis in HIV-1 infected patients.
Trans. R. Soc. Trop. Med. Hyg.
90:383[Medline].
|
| 15.
|
Gradoni, L.,
A. Scalone,
M. Gramiccia, and M. Troiani.
1996.
Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy.
AIDS
10:785-791[Medline].
|
| 16.
|
Gramiccia, M.,
L. Gradoni, and M. Troiani.
1995.
Heterogeneity among zymodemes of Leishmania infantum from HIV-positive patients with visceral leishmaniasis in south Italy.
FEMS Microbiol. Lett.
128:33-88[Medline].
|
| 17.
|
Martín Sánchez, J.,
F. Morillas Márquez,
A. Acedo Sánchez, and M. C. Sanchiz Marín.
1995.
The variability of the etiological agent of leishmaniasis in the north east of the Almeria Region, south-east Spain.
Syst. Parasitol.
30:233-238.
|
| 18.
|
Marty, P.,
Y. Le Fichoux,
F. Pratlong, and M. Gari-Toussaint.
1994.
Human visceral leishmaniasis in Alpes-Maritimes, France: epidemiological characteristics for the period 1985-1992.
Trans. R. Soc. Trop. Med. Hyg.
88:33-34[Medline].
|
| 19.
|
Medrano, F. J.,
J. Hernández-Quero,
E. Jiménez,
J. A. Pineda,
A. Rivero,
A. Sánchez-Quijano,
I. D. Vélez,
P. Viciana,
R. Castillo,
M. J. Reyes,
F. Carvajal, and E. Lissen.
1992.
Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?
AIDS
6:1499-1503[Medline].
|
| 20.
|
Parkas, V.,
J. Godwin, and H. W. Murray.
1997.
Kala-azar comes to New York.
Arch. Intern. Med.
157:921-923[Abstract].
|
| 21.
|
Piarroux, R.,
F. Gambarelli,
H. Dumon,
M. Fontes,
S. Dunan,
C. Mary,
B. Toga, and M. Quilici.
1994.
Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral leishmaniasis in immunocompromised patients.
J. Clin. Microbiol.
32:746-749[Abstract/Free Full Text].
|
| 22.
|
Pineda, J. A.,
J. Hernández-Quero,
J. A. Gallardo,
M. A. López-Ruz,
M. A. Martínez-Pérez,
J. Macías, and E. Lissen.
1996.
Frequency of subclinical visceral leishmaniasis in HIV-1 infected patients in Spain.
Eur. J. Clin. Microbiol. Infect. Dis.
15:263-264[Medline].
|
| 23.
|
Ribera, E.,
E. Cucurull,
I. Ocaña,
T. Vallespi,
I. Gasser, and C. Juste.
1995.
Leishmaniasis visceral en pacientes con infección por VIH.
Enf. Infecc. Microbiol. Clin.
13:73-79[Medline].
|
| 24.
|
Rioux, J. A.,
G. Lanotte,
E. Serres,
F. Pratlong,
P. Bastien, and J. Perières.
1990.
Taxonomy of leishmania. Use of isoenzymes. Suggestion for a new classification.
Ann. Parasitol. Hum. Comp.
65:111-125[Medline].
|
| 25.
|
Rosenthal, E.,
M. Marty,
I. Poizot-Martin,
J. Reynes,
F. Pratlong,
A. Lafeuillade,
D. Jaubert,
O. Boulat,
J. Dereure,
F. Gambarelli,
J. A. Gastaut,
P. Dujardin,
P. Dellamonica, and J. Cassuto.
1995.
Visceral leishmaniasis and HIV-1 co-infection in southern France.
Trans. R. Soc. Trop. Med. Hyg.
89:159-162[Medline].
|
Journal of Clinical Microbiology, September 1998, p. 2419-2422, Vol. 36, No. 9
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Garcia-Garcia, J. A., Martin-Sanchez, J., Gallego, M., Rivero-Roman, A., Camacho, A., Riera, C., Morillas-Marquez, F., Vergara, S., Macias, J., Pineda, J. A.
(2006). Use of Noninvasive Markers To Detect Leishmania Infection in Asymptomatic Human Immunodeficiency Virus-Infected Patients. J. Clin. Microbiol.
44: 4455-4458
[Abstract]
[Full Text]
-
Alvarez-Nebreda, M L, Alvarez-Fernandez, E, Rada, S, Branas, F, Maranon, E, Vidan, M T, Serra-Rexach, J A
(2005). Unusual duodenal presentation of leishmaniasis. J. Clin. Pathol.
58: 1321-1322
[Abstract]
[Full Text]
-
Vilaplana, C., Blanco, S., Dominguez, J., Gimenez, M., Ausina, V., Munoz, C.
(2004). Noninvasive Method for Diagnosis of Visceral Leishmaniasis by a Latex Agglutination Test for Detection of Antigens in Urine Samples. J. Clin. Microbiol.
42: 1853-1854
[Full Text]
-
MIRA, J. A., CORZO, J. E., RIVERO, A., MACIAS, J., DE LEON, F. L., TORRE-CISNEROS, J., GOMEZ-MATEOS, J., JURADO, R., PINEDA, J. A.
(2004). FREQUENCY OF VISCERAL LEISHMANIASIS RELAPSES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. Am J Trop Med Hyg
70: 298-301
[Abstract]
[Full Text]
-
Morehead, J., Coppens, I., Andrews, N. W.
(2002). Opsonization Modulates Rac-1 Activation during Cell Entry by Leishmania amazonensis. Infect. Immun.
70: 4571-4580
[Abstract]
[Full Text]
-
de la Rosa, R., Pineda, J. A, Delgado, J., Macias, J., Morillas, F., Mira, J. A., Sanchez-Quijano, A., Leal, M., Lissen, E.
(2002). Incidence of and Risk Factors for Symptomatic Visceral Leishmaniasis among Human Immunodeficiency Virus Type 1-Infected Patients from Spain in the Era of Highly Active Antiretroviral Therapy. J. Clin. Microbiol.
40: 762-767
[Abstract]
[Full Text]
-
Grech, V., Mizzi, J., Mangion, M., Vella, C.
(2000). Visceral leishmaniasis in Malta---an 18 year paediatric, population based study. Arch. Dis. Child.
82: 381-385
[Abstract]
[Full Text]
-
Lachaud, L., Dereure, J., Chabbert, E., Reynes, J., Mauboussin, J.-M., Oziol, E., Dedet, J.-P., Bastien, P.
(2000). Optimized PCR Using Patient Blood Samples For Diagnosis and Follow-Up of Visceral Leishmaniasis, with Special Reference to AIDS Patients. J. Clin. Microbiol.
38: 236-240
[Abstract]
[Full Text]